2009;54:1862 8. 27. Brennan JM, Edwards FH, Zhao Y, et al. Long-term safety and effective- ness of mechanical versus biologic aortic valve prostheses in older pa- tients: results from the Society of Thoracic Surgeons Adult Cardiac Surgery National Database. Circulation. 2013;127:1647 55. 28. Banbury MK, Cosgrove DM 3rd, Thomas JD, et al. Hemodynamic stability during 17 years of the Carpentier-Edwards aortic pericardial bioprosthesis. Ann Thorac Surg. 2002;73:1460 5. 29. Dellgren G, David TE, Raanani E, et al. Late hemodynamic and clinical out- comes of aortic valve replacement with the Carpentier-Edwards Perimount pericardial bioprosthesis. J Thorac Cardiovasc Surg. 2002;124:146 54. 30. Borger MA, Ivanov J, Armstrong S, et al. Twenty-year results of the Han- cock II bioprosthesis. J Heart Valve Dis. 2006;15:49 55. 31. Myk n PSU, Bech-Hansen O. A 20-year experience of 1712 patients with the Biocor porcine bioprosthesis. J Thorac Cardiovasc Surg. 2009;137:76 81. 32. Mazine A, El-Hamamsy I, Verma S, et al. Ross procedure in adults for car- diologists and cardiac surgeons: JACC state-of-the-art review. J Am Coll Cardiol. 2018;72:2761 77. 11.2. Antithrombotic Therapy 1. Cannegieter SC, Rosendaal FR, Bri t E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circula- tion. 1994;89:635 41. 2. Cannegieter SC, Rosendaal FR, Wintzen AR, et al. Optimal oral antico- agulant therapy in patients with mechanical heart valves. N Engl J Med. 1995;333:11 7. 3. Sun JCJ, Davidson MJ, Lamy A, et al. Antithrombotic management of pa- tients with prosthetic heart valves: current evidence and future trends. Lancet. 2009;374:565 76. 4. Van de Werf F, Brueckmann M, Connolly SJ, et al. A comparison of dabig- atran etexilate with warfarin in patients with mechanical heart valves: the Randomized, phase II study to Evaluate the sAfety and pharmacokinetics of oraL dabIGatran etexilate in patients after heart valve replacemeNt (RE- ALIGN). 